“The unique fusion of individual innovative technologies will provide a novel diagnostic tool leading to a better understanding of the underlying pathophysiology of rare anaemia.”

Lars Kaestner, Coordinator of CoMMiTMenT

About us

CoMMiTMenT has carefully selected its 9 partners from 6 European countries. The CoMMiTMenT consortium is of the very highest scientific, business and managerial calibre, guaranteeing the successful outcome of the proposed project. To ensure (i) the technological developments that are required to combine the imaging techniques and (ii) the application of this technology in rare anaemia related research, diagnosis and personalized medication, the consortium is composed of 4 SME partners (ORX, OpenIOLabs, arivis, Epigem), 4 clinical/academic partners (IDIBAPS, UMCU, USAAR, UZH) and Eurice as a management and dissemination partner. All of these organisations have a long-standing track record in their fields and are of considerable international standing. To aim of organising this consortium was to gather the best European specialists with the broadest experience for the task at hand.